Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price […]

Related Keywords

Robertw Baird , , Victory Capital Management Inc , Janssen Biotech Inc , Pricet Rowe Associates Inc , Mersana Therapeutics Inc , Merck Kga , Jpmorgan Chase Co , Asana Biosciences , Harbor Capital Advisors Inc , Russell Investments Group Ltd , Nisa Investment Advisors , Merck Kgaa , Nasdaq , Mersana Therapeutics , Get Free Report , Investments Group , Capital Advisors , Capital Management , Investment Advisors , Get Free , Janssen Biotech , Ares Trading , Mersana Therapeutics Daily ,